Garth Kroeker

Biases in Research  Pharmaceutical Research We are much more familiar these days with biases in pharmaceutical research studies.  A cli...

ADHD medication is a big business in the world today.  Annual sales of ADHD medication are projected to be 15-20 billion dollars by 2020, in...

It is common practice in psychiatry to increase the dose of an antidepressant if the standard dose is not helping enough.  Sometimes doses a...

A new Cochrane review, published on November 25, 2015 by authors Storebø and Zwi, looked at the use of stimulants to treat childhood ADHD (...

Duloxetine (Cymbalta) is another newer antidepressant, approved in the US in 2004, and in Canada in 2007.  It is a reuptake inhibitor of bot...

Vortioxetine is one of the newest antidepressants on the market, released in the U.S. in 2013.  It has serotonin and norepinephrine reuptake...

Desvenlafaxine (Pristiq) is an antidepressant that has been available since 2008-2009.  It is another example, similar to escitalopram, of a...

It is interesting how professional opinion can be swayed by trends in practice.   Escitalopram (Cipralex, or Lexapro) is a newer antidepres...

A supplement written by Christoph Correll for The Canadian Journal of Diagnosis (September 2009) was delivered--free--into my office mailbox...

Here's another article from "the last psychiatrist" on CME: http://thelastpsychiatrist.com/2009/07/who_should_pay_for_continui...

Around 2001, when I was a mood disorders fellow, I was asked to do an educational lecture by Organon, the manufacturer of the antidepressant...

There is evidence that research studies sponsored by pharmaceutical companies produce biased results. Here is a collection of papers suppor...